1
|
Martinez-Donato G, Amador-Cañizares Y, Alvarez-Lajonchere L, Guerra I, Pérez A, Dubuisson J, Wychowsk C, Musacchio A, Aguilar D, Dueñas-Carrera S. Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation. Vaccine 2014; 32:1720-6. [PMID: 24486345 DOI: 10.1016/j.vaccine.2014.01.046] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Revised: 01/06/2014] [Accepted: 01/15/2014] [Indexed: 01/01/2023]
Abstract
HCV is a worldwide health problem despite the recent advances in the development of more effective therapies. No preventive vaccine is available against this pathogen. However, non-sterilizing immunity has been demonstrated and supports the potential success of HCV vaccines. Induction of cross-neutralizing antibodies and T cell responses targeting several conserved epitopes, have been related to hepatitis C virus (HCV) clearance. Therefore, in this work, the immunogenicity of a preparation (MixprotHC) based on protein variants of HCV Core, E1, E2 and NS3 was evaluated in mice and monkeys. IgG from MixprotHC immunized mice and monkeys neutralized the infectivity of heterologous HCVcc. Moreover, strong CD4+ and CD8+ T cells proliferative and IFN-γ secretion responses were elicited against HCV proteins. Remarkably, immunization with MixprotHC induced control of viremia in a surrogate challenge model in mice. These results suggest that MixprotHC might constitute an effective immunogen against HCV in humans with potential for reducing the likelihood of immune escape and viral persistence.
Collapse
Affiliation(s)
- Gillian Martinez-Donato
- Center for Genetic Engineering and Biotechnology (CIGB), Ave 31, P.O. Box 6162, Havana, 10 600, Cuba.
| | - Yalena Amador-Cañizares
- Center for Genetic Engineering and Biotechnology (CIGB), Ave 31, P.O. Box 6162, Havana, 10 600, Cuba
| | - Liz Alvarez-Lajonchere
- Center for Genetic Engineering and Biotechnology (CIGB), Ave 31, P.O. Box 6162, Havana, 10 600, Cuba
| | - Ivis Guerra
- Center for Genetic Engineering and Biotechnology (CIGB), Ave 31, P.O. Box 6162, Havana, 10 600, Cuba
| | - Angel Pérez
- Center for Genetic Engineering and Biotechnology (CIGB), Ave 31, P.O. Box 6162, Havana, 10 600, Cuba
| | - Jean Dubuisson
- Institut de Biologie de Lille (UMR8161), CNRS, Universite de Lille I & II and Institut Pasteur de Lille, Lille, France
| | - Czeslaw Wychowsk
- Institut de Biologie de Lille (UMR8161), CNRS, Universite de Lille I & II and Institut Pasteur de Lille, Lille, France
| | - Alexis Musacchio
- Center for Genetic Engineering and Biotechnology (CIGB), Ave 31, P.O. Box 6162, Havana, 10 600, Cuba
| | - Daylen Aguilar
- Center for Genetic Engineering and Biotechnology (CIGB), Ave 31, P.O. Box 6162, Havana, 10 600, Cuba
| | - Santiago Dueñas-Carrera
- Center for Genetic Engineering and Biotechnology (CIGB), Ave 31, P.O. Box 6162, Havana, 10 600, Cuba
| |
Collapse
|